Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Binge Drinking of Alcohol Mixed With Energy Drinks (ENERGYBINGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04616859
Recruitment Status : Recruiting
First Posted : November 5, 2020
Last Update Posted : November 9, 2020
Sponsor:
Collaborator:
Germans Trias i Pujol Hospital
Information provided by (Responsible Party):
Fundació Institut Germans Trias i Pujol

Brief Summary:
The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)

Condition or disease Intervention/treatment Phase
Healthy Alcohol Drinking Dietary Supplement: Alcohol and Energy Drink (AmED) Dietary Supplement: Alcohol and Energy drink Placebo Dietary Supplement: Alcohol placebo and Energy drink Dietary Supplement: Alcohol placebo and energy drink placebo Not Applicable

Detailed Description:

Consumption of alcohol mixed with energy drinks (AmED) has increased mainly among young people. Energy drinks (ED) are usually combined with alcohol with the intention of counteracting its effects. However, most studies have not shown a reduction in drunkenness and consumption is related with engagement of risk-taking behaviours like driving under alcohol effects. It is already known that alcohol concentrations and effects are higher in women than in men even after adjusting dose by weight.

The relevance of gender in the acute effects of alcohol associated with ED consumed in a binge-drinking pattern has been poorly studied. A randomized clinical trial will be conducted in healthy volunteers (1:1) and four treatment conditions will be administered: alcohol+ED, alcohol+placebo of ED, placebo of alcohol+ED and placebo of alcohol+placebo of ED. Subjective and physiological effects, driving related skills, and alcohol and caffeine concentrations will be measured along an 8-hours period. A pilot study has been conducted with the first 6 volunteers to select the alcohol doses. In the definitive study 70 g of alcohol in men and 55 g in women will be used.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double-blind
Primary Purpose: Basic Science
Official Title: Combination of Alcohol and Energy Drinks in a Binge Drinking Pattern: Acute Effects and Gender Differences
Actual Study Start Date : October 8, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Ethanol

Arm Intervention/treatment
Experimental: Alcohol and Energy Drink (AmED)

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).

Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml

Dietary Supplement: Alcohol and Energy Drink (AmED)
Multiple oral dose of alcohol mixed with ED

Active Comparator: Alcohol and Energy drink Placebo

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).

Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)

Dietary Supplement: Alcohol and Energy drink Placebo
Multiple oral dose of alcohol mixed with ED placebo (soft drink)

Active Comparator: Alcohol placebo and Energy drink

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).

Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL

Dietary Supplement: Alcohol placebo and Energy drink
Multiple oral dose of alcohol placebo (water) mixed with ED

Placebo Comparator: Alcohol placebo and Energy drink placebo

The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).

Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL

Dietary Supplement: Alcohol placebo and energy drink placebo
Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)




Primary Outcome Measures :
  1. Change in subjective effects measured with Biphasic alcohol effects scale (BAES) [ Time Frame: From baseline to 8 hours after administration ]
    Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.

  2. Change in psychomotor vigilance task (PVT) [ Time Frame: From baseline to 6 hours after administration ]
    Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.


Secondary Outcome Measures :
  1. Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Calculation of AUC of ethanol blood concentrations. Obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  2. Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Obtained baseline and 0.15, 0.30 , 0.45, 1, 1.15,1.30, 1.45, 2, 2.15, 2.30, 3, 4, 6 and 8-h after administration.

  3. Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Calculation of AUC of caffeine concentrations obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  4. Maximum concentration (Cmax) of ethanol in blood [ Time Frame: From baseline to 8 hours after administration ]
    Maximum concentration (Cmax) of ethanol in blood

  5. Maximum concentration (Cmax) of caffeine in plasma [ Time Frame: From baseline to 8 hours after administration ]
    Maximum concentration (Cmax) of caffeine in plasma

  6. Time to reach maximum concentration (tmax) of ethanol in blood [ Time Frame: From baseline to 8 hours after administration ]
    Time to reach maximum concentration (tmax) of ethanol in blood

  7. Time to reach maximum concentration (tmax) of ethanol in breath air [ Time Frame: From baseline to 8 hours after administration ]
    Time to reach maximum concentration (tmax) of ethanol in breath air

  8. Time to reach maximum concentration (tmax) of caffeine in plasma [ Time Frame: From baseline to 8 hours after administration ]
    Time to reach maximum concentration (tmax) of caffeine in plasma

  9. Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Calculation of AUC of taurine concentrations obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration

  10. Maximum concentration (Cmax) of taurine plasma concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Maximum concentration (Cmax) of taurine plasma concentrations

  11. Time to reach maximum concentration (tmax) of taurine plasma concentrations [ Time Frame: From baseline to 8 hours after administration ]
    Time to reach maximum concentration (tmax) of taurine plasma concentrations

  12. Change in drunkenness feeling [ Time Frame: From baseline to 8 hours after administration ]
    Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  13. Change in dizziness feeling [ Time Frame: From baseline to 8 hours after administration ]
    Dizziness will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  14. Change in drowsiness feeling [ Time Frame: From baseline to 8 hours after administration ]
    Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  15. Change in palpitations reported by the participant [ Time Frame: From baseline to 8 hours after administration ]
    Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  16. Change in anxiety feeling [ Time Frame: From baseline to 8 hours after administration ]
    Anxiety will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  17. Change in headache [ Time Frame: From baseline to 8 hours after administration ]
    Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  18. Change in ability and predisposition to drive in certain situations [ Time Frame: From baseline to 8 hours after administration ]
    Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.30, 4, 6 and 8-h after administration.

  19. Desire to keep drinking [ Time Frame: At 1.30 hours ]
    Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.30 hours.

  20. Change in subjective effects measured with Addiction Research Center Inventory (ARCI) [ Time Frame: From baseline to 8 hours after administration ]
    Obtained baseline and 1, 1.45, 4, 6 and 8-h after administration.

  21. Change in blood pressure [ Time Frame: From baseline to 8 hours after administration ]
    Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  22. Change in heart rate [ Time Frame: From baseline to 8 hours after administration ]
    Heart rate (beats/min) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  23. Change in oral temperature [ Time Frame: From baseline to 8 hours after administration ]
    Oral temperature (ºC) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.

  24. Change in Maddox Wing score (MW) [ Time Frame: From baseline to 6 hours after administration ]
    Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.30, 4 and 6-h after administration.

  25. Beverage identification [ Time Frame: 8 hours after administration ]
    Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration

  26. Change in tracking test performance [ Time Frame: From baseline to 6 hours after administration ]
    Test will be performed using a computer program. Total time outside the road and number of errors will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.
  2. Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week [7 units, 70 g)]) and having experienced drunkenness several times
  3. Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.
  4. Understand and accept the study's procedures and sign an informed consent form.
  5. No evidence of somatic or psychiatric disorders as per past medical history and physical examination.
  6. The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

Exclusion Criteria:

  1. Not fill the inclusion criteria.
  2. Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.
  3. Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.
  4. Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.
  5. Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  6. Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial.
  7. Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.
  8. Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session.
  9. Smokers of >5 cigarettes/day
  10. Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  11. Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study.
  12. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  13. Subjects with positive serology to Hepatitis B, C or HIV.
  14. Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).
  15. Women with amenorrhea or suffering severe premenstrual syndrome.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04616859


Contacts
Layout table for location contacts
Contact: Clara Pérez-Mañá, MD,PhD +34 93 497 88 65 cperezm.mn.ics@gencat.cat
Contact: Magi Farré, MD, PhD +34 93 497 88 65 mfarre.germanstrias@gencat.cat

Locations
Layout table for location information
Spain
Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP) Recruiting
Badalona, Barcelona, Spain, 08916
Contact: Clara Pérez-Mañá, MD, PhD    +34 934978865    cperezm.mn.ics@gencat.cat   
Contact: Magi Farré, MD,PhD    +34 934978865    mfarre.germanstrias@gencat.cat   
Principal Investigator: Clara Pérez-Mañá, MD, PhD         
Sub-Investigator: Magí Farré, MD, PhD         
Sub-Investigator: Esther Papaseit, MD, PhD         
Sub-Investigator: Ana Maria Barriocanal, MD, PhD         
Sub-Investigator: Soraya Martin, RN         
Sub-Investigator: Alexandra Vila, RN         
Sub-Investigator: Olga Hladun, MD         
Sub-Investigator: Ana Pilar Pérez, MD         
Sub-Investigator: Melani Nuñez, MD         
Sub-Investigator: Lourdes Poyatos, BS         
Sponsors and Collaborators
Fundació Institut Germans Trias i Pujol
Germans Trias i Pujol Hospital
Investigators
Layout table for investigator information
Principal Investigator: Clara Pérez-Mañá, MD, PhD Hospital Universitari Germans Trias i Pujol-IGTP
Layout table for additonal information
Responsible Party: Fundació Institut Germans Trias i Pujol
ClinicalTrials.gov Identifier: NCT04616859    
Other Study ID Numbers: HUGTP/ENERGYBINGE/PNSD/1
HUGTP/ENERGYBINGE/PNSD/1 ( Other Identifier: Hospital Universitari Germans Trias i Pujol )
First Posted: November 5, 2020    Key Record Dates
Last Update Posted: November 9, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fundació Institut Germans Trias i Pujol:
alcohol binge drinking
alcohol
energy drinks
pharmacokinetics
caffeine
gender
Additional relevant MeSH terms:
Layout table for MeSH terms
Binge Drinking
Alcohol Drinking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs